Overview

Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% on Application of PROSE Devices for Management of Patients With Ocular Surface Disease

Status:
Recruiting

Trial end date:
2022-01-15

Target enrollment:

Participant gender:

Summary

The goal of this prospective observational pilot study is to evaluate the tolerability and safety of RESTASIS (cyclosporine ophthalmic solution 0.05%) when added to the PROSE (Prosthetic Replacement of the Ocular Surface Ecosystem) lens reservoir in patients with ocular surface disease (OSD). Secondary endpoints include early (1-month) efficacy data for ocular signs and symptoms.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Boston Sight

Collaborator:

Allergan

Treatments:

Cyclosporine
Cyclosporins
Ophthalmic Solutions